HealthBioArctic Says Novartis Ends Deal With Up to US$772 Million in Potential MilestonesBy Naomi CalderNov 2, 2026, 10:38 PM UTC
TechnologyCompanies Report AI Gains, but Most Do Not Quantify the PayoffBy Elias MercerNov 1, 2026, 7:12 AM UTC
HealthNovartis’ MS Candidate Meets Trial Goals as Entresto Faces Generic CompetitionBy Naomi CalderOct 30, 2026, 6:33 AM UTC
BusinessNovartis Raises 2026 Core Operating Income Outlook After Q3 GrowthBy Helena WardOct 27, 2026, 6:18 AM UTC
HealthNovartis Drug Lowers Annualized Relapse Rates by Up to 35.2% in MS TrialsBy Naomi CalderOct 24, 2026, 2:44 AM UTC
HealthNovartis Reports 19.1% Lower Death Risk in Six-Year Kisqali AnalysisBy Naomi CalderOct 23, 2026, 10:08 PM UTC
HealthClinicalTrials.gov Lists Novartis’ Iptacopan Study as TerminatedBy Naomi CalderOct 17, 2026, 9:44 AM UTC
BusinessRhizen Pharmaceuticals Announces Exclusive Worldwide License Agreement for the Development and Commercialization of a Dual PI3K-delta gamma InhibitorBy Nasdaq OMXDec 9, 2015, 12:00 PM UTC
